Data on safety and effectiveness of potential HAE treatment, deucrictibant, presented at 2025 ACAAI Annual Scientific Meeting
The latest data on a potential new medicine for HAE, deucrictibant, was presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting which took place in Orlando, Florida from 6-10 November 2025.
The following is a summary of some key findings:
- Open-label prophylaxis data supporting the long-term safety profile and sustained benefits of deucrictibant, as well as clinical validation data of a kinin biomarker assay were highlighted in two oral presentations
- Final data from participants in the open-label portion of the CHAPTER-1 study provide further evidence of a well-tolerated safety profile for up to approximately 34 months and an average of 92.4% attack reduction from study baseline with deucrictibant treatment
- Six additional posters detail the effectiveness, safety, and health-related quality of life outcomes from various clinical studies
Berndt Modig, Chief Executive Officer of Pharvaris, said: “We are proud about the recognition of the scientific community of the importance attributed to the late-stage confirmatory clinical data of deucrictibant and the associated biomarker work as oral presentations at the American College for Allergy, Asthma and Immunology annual conference. Beyond the scientific merit we are looking forward to the potential impact deucrictibant could have on the lives of people living with bradykinin-mediated angioedema.”
In an additional media communication, Pharvaris provided a series of operational updates. The key summaries were:
- Data from a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks is expected in the fourth quarter of 2025
- Data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks, is anticipated in 2H2026
- CREAATE, a pivotal Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks
Berndt Modig, Chief Executive Officer of Pharvaris, said: “We remain on track to report data from the pivotal Phase 3 trial, RAPIDe-3, in the fourth quarter of 2025. The achievement of this data readout, combined with the anticipated readout of CHAPTER-3 in the second half of next year, and the future outcome of the recently initiated CREAATE study, demonstrate our continued execution and commitment to develop new and innovative therapies for people with bradykinin-mediated diseases.”
(Source: Pharvaris)